| |
Diabetes
|
|
| |
|
|
| |
|
|
|
|
|
my personal edition > diabetes > news
E-Mail this DGDispatch to a colleague
DGDispatch
New Insulin Delivery System,, InnoLet, Eases Injections: Presented at IDF
By Jill Stein
PARIS, FRANCE -- August 26, 2003 -- A new insulin injection device, InnoLet, improves several measures of dose setting and injection administration relative to other injection devices, say researchers.
The device is thus useful for facilitating insulin injections, particularly in older patients, they announced on August 25th at the Eighteenth International Diabetes Federation (IDF) Congress.
Dr. Tatsuya Muto and colleagues at Aichi Medical University Hospital in Aichi, Japan, tested the device in 71 diabetics who had been using insulin injections pens for 4 months and who then switched to InnoLet on the advice of their physicians.
"Increasingly, insulin injection devices are being developed to target the needs of specific groups of diabetes patients such as children and the elderly," Dr. Muto pointed out. In Japan, several injection devices are currently available but the choice of device is often made without clear selection criteria. As a result, patients may not receive that the device that most suits them, he said.
InnoLet has a unique box shape with a large analogue dosing dial and push button aimed at facilitating insulin injections in diabetic patients who also have visual impairment, diminished dexterity, or learning difficulties.
In this study, on the first day of InnoLet use, patients rated the functionality of their prior pens on several measures including ease of grip, ease of pressing push button, weight, stability at injection time, legibility of the dose scale, simplicity, ease of dose setting, and portability. After a minimum of 3 days use, patients rated InnoLet on the same measures of functionality.
Compared to their previous injection pens, patients rated InnoLet as providing better dose scale legibility (p < 0.001), greater ease of dose setting (p < 0.001), easier pressing of bush button (p < 0.01), increased simplicity (p < 0.001), and better overall usability (p < 0.01).
There were no significant differences in the ratings given to previous injection pens and InnoLet on measures of weight and stability at injection time.
Overall, InnoLet scored significantly lower on measures of ease of grip and portability than the previously used pens. Analysis by age group shows that the younger patients in particular found InnoLet harder to hold and less portable.
There was no significant difference in measures of grip or portability between InnoLet and previously used pens in the older patient groups.
Dr. Muto emphasized that while the results document the utility of InnoLet in diabetic patients, treatment must be tailored to the individual to ensure that the most appropriate delivery dos device is prescribed.
The study was sponsored by Novo Nordisk in Bagsvaerd, Denmark.
[Study title: A comparative study of the efficacy of the new insulin delivery device "InnoLet" versus insulin pens. Abstract 2235]
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
|
